jnj

The Carlyle Group has agreed to buy Johnson & Johnson’s Ortho-Clinical Diagnostics (OCD) business for $4.15bn.

The transaction is subject to customary regulatory approvals and is slated to close in the middle of 2014.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

With this acquisition, Carlyle plans to tap into emerging and established markets and make accelerated investments in research and product development.

Provider of solutions for screening, diagnosing, monitoring and confirming diseases, OCD, is headquartered in Raritan, New Jersey, with manufacturing operations in Rochester, New York, Pompano Beach, Florida and Pencoed, Wales.

It operates in 130 countries and serves clinical laboratories and the transfusion medicine community globally.

The Carlyle Group managing director Stephen H Wise said: “We have been focused on the diagnostics industry for many years given its attractive growth prospects, driven by the crucial role it plays in health care decision-making and influencing patient outcomes.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“We have been focused on the diagnostics industry for many years given its attractive growth prospects, driven by the crucial role it plays in health care decision-making and influencing patient outcomes.”

Carlyle will pay for the transaction with equity from its $13bn US Buyout fund, Carlye Partners VI, which completed fundraising in November 2013 with 269 investors from 43 countries.

Ortho-Clinical Diagnostics worldwide president Eric Compton said: “In combination with Carlyle’s global reach and deep experience in the healthcare sector, OCD will have the opportunity to invest in new, innovative products and services for its customers and provide an environment for its professionals to excel in a competitive global marketplace.”

Carlyle has invested $6.3bn of equity in healthcare transactions around the globe to date, while current and former investments include Pharmaceutical Product Development (PPD), Grupo Qualicorp, Healthscope Limited, HCR ManorCare and MultiPlan.

Barclays and Goldman Sachs are acting as financial advisors to The Carlyle Group, which has secured committed debt financing from Barclays, Goldman Sachs, Credit Suisse, UBS and Nomura. Latham & Watkins LLP is acting as legal advisor to The Carlyle Group.


Image: Johnson & Johnson headquarters in New Brunswick, New Jersey. Photo: courtesy of Ekem.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact